Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Drug Development and Registration
ISSN 2305-2066 · eISSN 2658-5049 · Center of Pharmaceutical Analytics · Russian Federation
Drug Development and Registration: fully open access; APC charged, amount not published; review about 8 weeks (community reports); 81 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Drug Development and Registration is published by Center of Pharmaceutical Analytics. By OpenAlex counts of its recent articles, its largest topics are Analytical Methods in Pharmaceuticals, Medical and Pharmaceutic Studies and Advanced Drug Delivery Systems, together about 38% of its articles. Its main subfields are Plant Science. (generated from OpenAlex topic counts and CAS ranking data)
Научно-практический журнал общемедицинского профиля «Разработка и регистрация лекарственных средств» является регулярным рецензируемым печатным изданием, отражающим результаты передовых исследований фармацевтической отрасли. Журнал публикует оригинальные и обзорные научные статьи по темам: поиск и разработка новых лекарственных средств; фармацевтическая технология; методы анализа лекарственных средств; доклинические и клинические исследования; регуляторные вопросы.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Main research topics OpenAlex counts of recent articles; shares are approximate
- Analytical Methods in PharmaceuticalsChemistry17.7%
- Medical and Pharmaceutic StudiesPharmacology, Toxicology and Pharmaceutics10.7%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics9.6%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics9.2%
- Medicinal Plant ResearchAgricultural and Biological Sciences8.1%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology4%
- Phytochemistry Medicinal Plant ApplicationsAgricultural and Biological Sciences3.2%
- Forensic Toxicology and Drug AnalysisPharmacology, Toxicology and Pharmaceutics2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacy | Q3 | 30/52 | 43rd |
| Pharmaceutical Science | Q3 | 135/191 | 29th |
| Drug Discovery | Q4 | 141/161 | 12th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SCIEPublisher website
Other: РИНЦ, Перечень ВАК (категория К1)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 1.1LetPub ·
- SJR 2026-06
- 0.19LetPub ·
- SNIP 2026-06
- 0.31LetPub ·
- h-index
- 11OpenAlex ·
- i10-index
- 19OpenAlex ·
- 2-year mean citedness
- 0.74OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 948 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 59 | 59 | 258 |
| 2025 | 81 | 81 | 335 |
| 2024 | 99 | 99 | 302 |
| 2023 | 119 | 119 | 278 |
| 2022 | 108 | 108 | 194 |
| 2021 | 113 | 113 | 144 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | RUB 49,000 | Yes | CC BY | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 250–300 words
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted13
- воспоминанияВОСПОМИНАНИЯ Свободная подача рукописей Индексация С рецензированиемLength not stated
- дискуссииДИСКУССИИ Свободная подача рукописей Индексация С рецензированиемLength not stated
- доклинические и клинические исследованияДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ Свободная подача рукописей Индексация С рецензированиемLength not stated
- исправленияИСПРАВЛЕНИЯ Свободная подача рукописей Индексация С рецензированиемLength not stated
- материалы студенческой научной школыМАТЕРИАЛЫ СТУДЕНЧЕСКОЙ НАУЧНОЙ ШКОЛЫ Свободная подача рукописей Индексация С рецензированиемLength not stated
- методы анализа лекарственных средствМЕТОДЫ АНАЛИЗА ЛЕКАРСТВЕННЫХ СРЕДСТВ Свободная подача рукописей Индексация С рецензированиемLength not stated
- некрологНЕКРОЛОГ Свободная подача рукописей Индексация С рецензированиемLength not stated
- поиск и разработка новых лекарственных средствПОИСК И РАЗРАБОТКА НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ Свободная подача рукописей Индексация С рецензированиемLength not stated
- практические рекомендацииПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ Свободная подача рукописей Индексация С рецензированиемLength not stated
- регуляторные вопросыРЕГУЛЯТОРНЫЕ ВОПРОСЫ Свободная подача рукописей Индексация С рецензированиемLength not stated
- фармацевтическая технологияФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ Свободная подача рукописей Индексация С рецензированиемLength not stated
- юбилеиЮБИЛЕИ Свободная подача рукописей Индексация С рецензированиемLength not stated
- юбилейЮБИЛЕЙ Свободная подача рукописей Индексация С рецензированиемLength not stated
Policy excerpts from the journal's websiteOpen access, Peer review, Plagiarism
- Open access
Политика свободного доступа: непосредственный открытый доступ к контенту. Model summary
Этот журнал предоставляет непосредственный открытый доступ к своему контенту, исходя из следующего принципа: свободный открытый доступ к результатам исследований способствует увеличению глобального обмена знаниями.
Source ↗Publisher website ·- Peer review
Обязательное двойное слепое рецензирование всех научных статей. Model summary
Все научные статьи, поступившие в редакцию журнала «Разработка и регистрация лекарственных средств», проходят обязательное двойное слепое рецензирование (рецензент не знает авторов рукописи, авторы рукописи не знаю рецензентов).
Source ↗Publisher website ·- Plagiarism
Архивация в РГБ и НЭИКОН. Model summary
Архивация Российская Государственная Библиотека Национальный Электронно-Информационный Консорциум
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Center of Pharmaceutical Analytics
- Country or region
- Russian Federation
- Language
- Russian
- ISSN
- 2305-2066
- Electronic ISSN
- 2658-5049
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Drug Development and Registration
How long does peer review take at Drug Development and Registration?
Authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Drug Development and Registration?
According to the journal's author guidelines: Abstract: 250–300 words; Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Drug Development and Registration?
According to LetPub and DOAJ records, Drug Development and Registration is indexed in Scopus and DOAJ. The journal's website also lists SCIE; that list has not been checked against each database.
Is Drug Development and Registration open access, and what is the APC?
Drug Development and Registration is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .